does umr cover tirzepatide UnitedHealthcare (Mounjaro) Welcome to UMR

Clinical Evidence for Blood Sugar Control The SUSTAIN trial series, which followed thousands of adults with type 2 diabetes over 30+ weeks, demonstrated that semaglutide reduced fasting blood glucose by 1822 mg/dL and lowered HbA1c from baseline by 1.51.8%

It promotes fat storage in the abdominal area

A provider evaluation is needed before considering any peptide therapy

Our team of board-certified physicians and experienced healthcare providers are dedicated to delivering exceptional, patient-centered care in a welcoming and compassionate environment

Patients who began at the lowest dose and escalated gradually may reach 812% by month six, while those who reached therapeutic doses earlier often see 15% or more

VIDEO INSTRUCTIONS WHY DO WE DO THIS TEST